Solve Therapeutics raised $120 million to advance two antibody‑drug conjugates (ADCs), and the company said the financing will support ongoing preclinical and early clinical development. Backed by investors including former VelosBio team members and Merck among others, Solve claims proprietary linker technology that could address limitations of prior ADC platforms. Company disclosures indicate the funds will underwrite IND‑enabling studies and initial human testing, though the targets and payloads remain undisclosed. The round underscores investor appetite for ADC startups that promise next‑generation linker and payload chemistry to expand therapeutic windows.